TY - JOUR AU - Ladekarl, Morten PY - 2023 TI - Pembrolizumab for second line treatment of advanced hepatocellular carcinoma—who would benefit? JF - Chinese Clinical Oncology; Vol 12, No 2 (April 28, 2023): Chinese Clinical Oncology Y2 - 2023 KW - N2 - UR - https://cco.amegroups.org/article/view/111266